Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau183lec

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 27	MAR 23	CA/CAplus enhanced with more than 250,000 patent

equivalents from China

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009

=>
=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading A:\10.530851.R1.Meutermans et al..SRNT.CAPLUS..str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

```
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:32:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7138 TO ITERATE

 28.0% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       137695 TO   147825
PROJECTED ANSWERS:           22111 TO    26283

L2           50 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:32:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   142816 TO ITERATE

100.0% PROCESSED   142816 ITERATIONS                          23950 ANSWERS
SEARCH TIME: 00.00.02

L3        23950 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     188.28     188.50

FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Mar 2009  VOL 150 ISS 14
FILE LAST UPDATED: 27 Mar 2009  (20090327/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html
```

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1   STRUCTURE UPLOADED
L2   50 S L1 SSS SAM
L3   23950 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009

=> s l3
L4   8909 L3

=> s l4 and g (w) protein (w) coupled (w) receptor
       3202732 G
       2284371 PROTEIN
        397732 COUPLED
        797776 RECEPTOR
         11324 G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L5   2 L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR

=> d l5 ed ibib abs hitstr 1-2

L5   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ED   Entered STN: 19 Oct 2001
ACCESSION NUMBER: 2001:763315 CAPLUS
DOCUMENT NUMBER: 135:314480
TITLE: Polynucleotides and polypeptides for mammalian T2R
                          taste receptors and their uses
INVENTOR(S):   Adler, Jon Elliot
PATENT ASSIGNEE(S):   Senomyx, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
     ---------------   ----   --------   --------------------   --------
     WO 2001077676   A1   20011018   WO 2001-US10739   20010404
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2403003   A1   20011018   CA 2001-2403003   20010404
     EP 1292827   A1   20030319   EP 2001-924619   20010404
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003530098   T   20031014   JP 2001-574481   20010404
     AU 2001251258   B2   20080605   AU 2001-251258   20010404

NO 2002004809	A	20021209	NO 2002-4809		20021004
MX 2002009843	A	20040906	MX 2002-9843		20021004
US 20040209313	A1	20041021	US 2003-724208		20031201
US 7399601	B2	20080715			
US 20040248149	A1	20041209	US 2003-724209		20031201
US 7393654	B2	20080701			
US 20050069944	A1	20050331	US 2004-986871		20041115
US 7396651	B2	20080708			
US 20070059759	A1	20070315	US 2006-599313		20061115
US 20070061902	A1	20070315	US 2006-599318		20061115
US 20070061903	A1	20070315	US 2006-599319		20061115
US 20070061904	A1	20070315	US 2006-599346		20061115
US 20070061905	A1	20070315	US 2006-599360		20061115
US 20070061906	A1	20070315	US 2006-599392		20061115
US 20070065870	A1	20070322	US 2006-599467		20061115
US 20070065871	A1	20070322	US 2006-599472		20061115
US 20070065873	A1	20070322	US 2006-599487		20061115
AU 2008200999	A1	20080320	AU 2008-200999		20080303
US 20080305542	A1	20081211	US 2008-122052		20080516
US 20090017537	A1	20090115	US 2008-133155		20080604
AU 2008212000	A1	20080925	AU 2008-212000		20080904
PRIORITY APPLN. INFO.:			US 2000-195532P	P	20000407
			US 2000-247014P	P	20001113
			AU 2001-251258	A3	20010404
			WO 2001-US10739	W	20010404
			US 2001-825882	A3	20010405
			AU 2002-318229	A3	20020710
			US 2003-724208	A3	20031201
			US 2003-724209	A1	20031201

AB Newly identified mammalian taste-cell-specific G protein-coupled receptors and cDNAs for said receptors are claimed. Specifically, human and mouse T2R taste G protein-coupled receptors that are believed to be involved in bitter taste sensation are described, along with methods for isolating genes encoding the same and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel mols. or combinations of mols. that elicit a predetd. taste perception in a mammal, and methods for simulating one or more tastes. The identification and isolation of novel taste receptors and taste signaling mols. could allow for new methods of chemical and genetic modulation of taste transduction pathways. Identification of taste modulating compds. could be useful in the pharmaceutical and food industries to improve the taste of consumer products or to block undesirable tastes, for example bitter tastes, in certain products.

IT 6424-12-0, Raffinose undecaacetate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ligand; polynucleotides and polypeptides for mammalian T2R taste receptors and their uses)

RN 6424-12-0 CAPLUS

CN α-D-Glucopyranoside, 1,3,4,6-tetra-O-acetyl-β-D-fructofuranosyl O-2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl-(1→6)-, 2,3,4-triacetate (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 14 May 1998
ACCESSION NUMBER: 1998:275263 CAPLUS
DOCUMENT NUMBER: 128:257627
ORIGINAL REFERENCE NO.: 128:51003a,51006a
TITLE: Modulation of Receptor and Receptor Subtype Affinities Using Diastereomeric and Enantiomeric Monosaccharide Scaffolds as a Means to Structural and Biological Diversity. A New Route to Ether Synthesis
AUTHOR(S): Hirschmann, Ralph; Hynes, John, Jr.; Cichy-Knight, Maria A.; van Rijn, Rachel D.; Sprengeler, Paul A.; Spoors, P. Grant; Shakespeare, William C.; Pietranico-Cole, Sherrie; Barbosa, Joseph; Liu, Josephine; Yao, Wenqing; Rohrer, Susan; Smith, Amos B., III
CORPORATE SOURCE: Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(9), 1382-1391
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We show that carbohydrates constitute an attractive source of readily available, stereochem. defined scaffolds for the facile attachment of side chains contained in genetically encoded and other amino acids. β-D- And β-L-glucose, L-mannose, and the 6-deoxy-6-N-analog of β-D-glucose have been employed to synthesize peptido-mimetics that bind the SRIF receptors on AtT-20 mouse pituitary cells, five cloned human receptor subtypes (hSSTRs), and the NK-1 receptor. The affinity profile of various sugar-based ligands at the hSSTRs is compared with that of SRIF. Subtle structural changes affect affinities. The SARs of the glycosides at SRIF receptors differ markedly from those at the NK-1 receptor. A new method for the synthesis of base-sensitive ethers from primary and secondary alcs. is also described.

IT 132132-78-6 149831-71-0 170219-26-8
205440-97-7 205440-98-8 205440-99-9
205441-00-5 205441-01-6 205441-02-7

205441-04-9 205441-06-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biol. diversity)

RN 132132-78-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 149831-71-0 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-26-8 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(5-hydroxypentyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205440-97-7 CAPLUS
CN β-L-Glucopyranoside, 2-(1H-indol-3-yl)ethyl
6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205440-98-8 CAPLUS
CN β-L-Mannopyranoside, 2-(1H-indol-3-yl)ethyl
6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205440-99-9 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-aminopentyl)-2-O-(1H-imidazol-4-ylmethyl)-3,4-bis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205441-00-5 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-aminopentyl)-3-O-(1H-imidazol-4-ylmethyl)-2,4-bis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205441-01-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-[acetyl(5-hydroxypentyl)amino]-6-deoxy-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205441-02-7 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-[(5-aminopentyl)amino]-6-deoxy-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205441-04-9 CAPLUS
CN β-L-Mannopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(5-aminopentyl)-2-O-(1H-imidazol-4-ylmethyl)-3,4-bis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205441-06-1 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-[5-(acetylamino)pentyl]-2-O-[(4-fluorophenyl)methyl]-3,4-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 170220-03-8
RL: PRP (Properties)
(modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biol. diversity)
RN 170220-03-8 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-azidopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 23950 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4 8909 S L3
L5 2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR

=> s l3 and protein
8909 L3
2284371 PROTEIN
L6 429 L3 AND PROTEIN

=> s l6 and inhibit?
2126139 INHIBIT?
L7 102 L6 AND INHIBIT?

=> s l7 and pain
66609 PAIN
L8 4 L7 AND PAIN

=> d l8 ed ibib abs hitstr 1-4

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 22 May 2008
ACCESSION NUMBER: 2008:607923 CAPLUS
DOCUMENT NUMBER: 148:586080
TITLE: Preparation of aminodeoxy sugar sulfates as antiinflammatory and antiproliferative agents
INVENTOR(S): Seed, Michael Peter; Burnet, Michael; Gutcke, Hans Juergen
PATENT ASSIGNEE(S): Diosamine Development Corporation, USA
SOURCE: PCT Int. Appl., 115pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2008059003	A1	20080522	WO 2007-EP62355	20071114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-22688 A 20061114
GB 2007-11138 A 20070611

OTHER SOURCE(S): MARPAT 148:586080

GI



I

AB Title compds. were prepared and comprising: (i) at least one monosaccharide subunit comprising a glycosidic -NR2, a glycosidic -NR3+, =NR, or a directly bonded =NR2+, wherein each R is independently hydrogen, a -SO-OR' or -SO-N(R')2, a further monosaccharide subunit, or a hydrocarbyl, or two or three Rs and the nitrogen atom to which they are attached, together form a further monosaccharide subunit or a cyclic hydrocarbyl; and [ii] at least one sulfate, wherein a sulfate is a -O-SO2-OR', -NR'-SO2-OR', -O-SO2-N(R')2 or -NR'-SO2-N(R')2; wherein each R' is independently hydrogen, a metal, a further monosaccharide subunit, or a hydrocarbyl; wherein each monosaccharide subunit independently is optionally substituted and/ or optionally modified; and wherein each hydrocarbyl independently is a substituted or unsubstituted, straight-chain, branched or cyclic alkyl, alkenyl, alkynyl, acyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl which optionally includes one or more heteroatoms in its carbon skeleton. Such compds. may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound

healing, depression, and other diseases and disorders. Thus, monosaccharide I was prepared and tested as as antiinflammatory and antiproliferative agent.

IT 63976-10-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminodeoxy sugar sulfates as antiinflammatory and antiproliferative agents)

RN 63976-10-3 CAPLUS

CN β-D-Glucopyranosylamine, N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ED Entered STN: 28 Mar 2002

ACCESSION NUMBER: 2002:240217 CAPLUS

DOCUMENT NUMBER: 137:118909

TITLE: Drug design at peptide receptors: somatostatin receptor ligands

AUTHOR(S): Hannon, Jason P.; Nunn, Caroline; Stolz, Barbara; Bruns, Christian; Weckbecker, Gisbert; Lewis, Ian; Troxler, Thomas; Hurth, Konstanze; Hoyer, Daniel

CORPORATE SOURCE: Nervous System, Novartis Pharma AG, Basel, CH-4002, Switz.

SOURCE: Journal of Molecular Neuroscience (2002), 18(1/2), 15-27
CODEN: JMNEES; ISSN: 0895-8696

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Somatostatin (SRIF, somatotropin release inhibiting factor), discovered for its inhibitory action on growth hormone (GH) secretion from pituitary, is an abundant neuropeptide. Two forms, SRIF14 and SRIF28 exist. Recently, a second family of peptides with very similar sequences and features was described; the cortistatins (CST), CST17 and CST29 which are brain selective. The five cloned SRIF receptors (sst1-5) belong to the G-protein coupled/heptathelical receptor family. Structural and operational features distinguish two classes of receptors; SRIF1-sst2/sst3/sst5 (high affinity for octreotide or seglitide) and SRIF2=sst1/sst4 (very low affinity for the aforementioned ligands). The affinity of SRIF receptors for somatostatins and cortistatins is equally high, and it is not clear whether selective receptors do exist for one or the other of the peptides. Several radiologlands label all SRIF receptors, e.g., [125I] LTT-SRIF28, [125I] CGP23996, [125I] Tyr10cortistatin or [125I] Tyr11SRIF14. In contrast, [125I] Tyr3octreotide, [125I] BIM23027, [125I] MK678 or [125I]

D-Trp8SRIF14 label predominantly SRIF1 sites, especially sst2 and possibly sst5 receptors. In brain, [125I]Tyr3octreotide binding equates with sst2 receptor mRNA distribution. Native SRIF2 receptors can be labeled with [125I]SRIF14 in the presence of high NaCl in brain (sst1) or lung (sst4) tissue. Short cyclic or linear peptide analogs show selectivity for sst2/sst5 (octreotide, lanreotide, BIM 23027), sst1 (CH-275), sst3 (sst3-ODN-8), or sst5 receptors (BIM 23268); although claims for selectivity have not always been confirmed. Beta peptides with affinity for SRIF receptors are also reported. The general lack of SRIF receptor antagonists is unique for peptide receptors, although CYN 154806 is a selective and potent sst2 antagonist. Nonpeptide ligands are still rare, although a number of mols. have been reported with selectivity and potency for sst1 (L757,519), sst2 (L779,976), sst3 (L796,778), sst4 (NNC 26-9100, L803,087) or sst1/sst5 receptors (L817,018). Such mols. are essential to establish the role of SRIF receptors, e.g., sst1 in hypothalamic glutamate currents: sst2 in inhibiting release of GH, glucagon, TSH, gastric acid secretion, pain, seizures and tumor growth, and sst5 in vascular remodeling and inhibition of insulin and GH release.

IT 132132-78-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(drug design at peptide receptors for somatostatin receptor ligands)

RN 132132-78-6 CAPLUS

CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 30 Sep 1998
ACCESSION NUMBER: 1998:618388 CAPLUS
DOCUMENT NUMBER: 129:245490
ORIGINAL REFERENCE NO.: 129:50001a,50004a
TITLE: Preparation of carbohydrate and cyclopeptide mimetics binding to G-protein-linked receptors
INVENTOR(S): Hirschmann, Ralph F.; Sprengeler, Paul; Yao, Wenqing
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: U.S., 69 pp., Cont.-in-part of U.S. 5,552,534.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5811512	A	19980922	US 1996-588773		19960119
US 5552534	A	19960903	US 1993-144660		19931028
WO 9728172	A1	19970807	WO 1997-US1097		19970117
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9717538	A	19970822	AU 1997-17538		19970117
PRIORITY APPLN. INFO.:			US 1991-748826	B2	19910822
			US 1993-144660	A2	19931028
			US 1996-588773	A	19960119
			WO 1997-US1097	W	19970117

OTHER SOURCE(S): MARPAT 129:245490

GI



I II

AB Compds. are provided which are crossreactive with peptides such as those which bind G-protein-linked receptors, together with preparative and therapeutic methods therefor. Hexose derivs. I [R1 = Me, 3-indolylethyl; R2, R3 = PhCH2; R4 = H, PhCH2; R5 = CH2OH, (CH2)5NH2, (CH2)5NHAc] bearing functional groups which cross-react with peptides which bind G-protein-linked receptors, such as substance P receptors, are prepared for use in treatment of diseases characterized by the presence of excess tachykinin. These diseases include central nervous disorders (e.g. Alzheimer's disease), respiratory diseases (e.g. asthma), inflammatory diseases (e.g. rheumatoid arthritis), adverse immunol. reactions (e.g.transplant rejection), gastrointestinal disorders (e.g. ulcerative colitis), and pain (e.g. migraine). In another aspect, the invention claims cyclic hexapeptides II (R10 = indolyl; R11 = H, CHMe2, Ph, C6H4OH-4, C6H4OMe-4, fluorophenyl; R12 = Ph; R13 = OH, CO2H, H, indolyl, Ph, CH2Ph, cyclohexyl,naphthyl). Thus, side-chain protected linear hexapeptides were prepared by solid-phase methods using 9-fluorenylmethoxycarbonyl (Fmoc) protection on a chlorotrityl polystyrene resin, cleaved from the resin with 0.25% CF3CO2H in CH2Cl2, cyclized with DPPA in DMF, and deprotected with CF3CO2H to give desired cyclohexapeptides II. Eighteen II were tested as inhibitors of HIV-1 protease, showing IC50 values of 9000 to 2.8 nM, with II (R10 = 3-indolyl, R11 = C6H4F-4, R12 = Ph, R13 = 1-naphthyl) being the most active.

IT 132132-78-6P 144191-86-6P 149831-66-3P

149831-67-4P 149831-71-0P 149831-93-6P
155044-80-7P 164026-07-7P 170219-19-9P
170219-20-2P 170219-26-8P 170219-27-9P
170219-28-0P 183050-66-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbohydrate and cyclopeptide mimetics binding to G-protein-linked receptors)

RN 132132-78-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 144191-86-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 149831-66-3 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(4-aminobutyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 149831-67-4 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(6-aminohexyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 149831-71-0 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 149831-93-6 CAPLUS
CN β-D-Glucopyranoside, methyl 2,3,4-tris-O-(phenylmethyl)-6-O-[5-[(trifluoroacetyl)amino]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155044-80-7 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 164026-07-7 CAPLUS
CN β-D-Glucopyranoside, methyl 6-deoxy-6-[(5-hydroxypentyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-19-9 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-[5-(benzoylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-20-2 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(5-hydroxypentyl)(trifluoroacetyl)amino]-2,3,4-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-26-8 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(5-hydroxypentyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-27-9 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(4-hydroxybutyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-28-0 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(6-hydroxyhexyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183050-66-0 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 149831-99-2P 170219-35-9P 170219-61-1P
170219-82-6P 170219-83-7P 170219-85-9P
170219-87-1P 170220-03-8P 183051-10-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbohydrate and cyclopeptide mimetics binding to G-

protein-linked receptors)

RN 149831-99-2 CAPLUS

CN 1H-Indole, 3-[2-[[6-O-[5-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)pentyl]-2-O-[(methylthio)thioxomethyl]-3,4-bis-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-35-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-3-[2-[[2,3,4-tris-O-(phenylmethyl)-6-O-[5-[(trifluoroacetyl)amino]pentyl]-β-D-glucopyranosyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-61-1 CAPLUS

CN 1H-Indole, 3-[2-[[6-deoxy-6-[(5-hydroxypentyl)(trifluoroacetyl)amino]-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-82-6 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(5-azidopentyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-83-7 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-85-9 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(6-azidohexyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 170219-87-1 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(6-aminohexyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 170220-03-8 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-azidopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183051-10-7 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-butyl-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 28 Sep 1996
ACCESSION NUMBER: 1996:577852 CAPLUS
DOCUMENT NUMBER: 125:317374
ORIGINAL REFERENCE NO.: 125:59139a,59142a
TITLE: Nonpeptide peptidomimetics binding to G-protein-linked receptors
INVENTOR(S): Hirschmann, Ralph F.; Nicolaou, Kyriacos C.; Pietranico, Sherrie; Reisine, T. R.; Salvino, Joseph M.; Sprengeler, Paul; Strader, Catherine D.
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 748,826, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5552534	A	19960903	US 1993-144660	19931028
CA 2175195	A1	19950504	CA 1994-2175195	19941026
WO 9511686	A1	19950504	WO 1994-US12233	19941026
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 728007	A1	19960828	EP 1994-932029	19941026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5811512	A	19980922	US 1996-588773	19960119

PRIORITY APPLN. INFO.: US 1991-748826 B2 19910822
US 1993-144660 A 19931028
WO 1994-US12233 W 19941026

OTHER SOURCE(S): MARPAT 125:317374
GI



I

AB Hexose derivs. [I; R1 = Me, 3-indolylethyl; R2, R3 = PhCH2; R4 = H, PhCH2; R5 = CH2OH, (CH2)5NH2, (CH2)5NHCOMe] bearing functional groups which cross-react with peptides which bind G-protein-linked receptors, such as substance P receptors, are prepared for use in treatment of diseases characterized by the presence of excess tachykinin. These diseases include central nervous disorders (e.g. Alzheimer's disease), respiratory diseases (e.g. asthma), inflammatory diseases (e.g. rheumatoid arthritis), adverse immunol. reactions (e.g.transplant rejection), gastrointestinal disorders (e.g. ulcerative colitis), and pain (e.g. migraine). Thus, I [R1 = 2-(1-phenylsulfonylindol-3-yl)ethyl, R2-R4 = PhCH2, R5 = (CH2)5NH2] inhibited binding of substance P to the human neurokinin-1 receptor (expressed in COS cells) with an IC50 of 120 nM.

IT 132132-78-6P 144191-86-6P 149831-66-3P
149831-67-4P 149831-71-0P 149831-93-6P
155044-80-7P 164026-07-7P 170219-19-9P
170219-20-2P 170219-26-8P 170219-27-9P
170219-28-0P 183050-66-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nonpeptide peptidomimetics binding to G-protein-linked receptors)

RN 132132-78-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 144191-86-6 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 149831-66-3 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl
6-O-(4-aminobutyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 149831-67-4 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl
6-O-(6-aminohexyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 149831-71-0 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-aminopentyl)-2,3,4-tris-O-
(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 149831-93-6 CAPLUS
CN β-D-Glucopyranoside, methyl 2,3,4-tris-O-(phenylmethyl)-6-O-[5-
[(trifluoroacetyl)amino]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155044-80-7 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 164026-07-7 CAPLUS
CN β-D-Glucopyranoside, methyl 6-deoxy-6-[(5-hydroxypentyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-19-9 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-O-[5-(benzoylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-20-2 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(5-hydroxypentyl)(trifluoroacetyl)amino]-2,3,4-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-26-8 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(5-hydroxypentyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-27-9 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(4-hydroxybutyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-28-0 CAPLUS
CN β-D-Glucopyranoside, 2-(1H-indol-3-yl)ethyl 6-deoxy-6-[(6-hydroxyhexyl)amino]-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 183050-66-0 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-[5-(acetylamino)pentyl]-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 149831-99-2P 170219-35-9P 170219-61-1P
170219-82-6P 170219-83-7P 170219-85-9P
170219-87-1P 170220-03-8P 183051-10-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nonpeptide peptidomimetics binding to G-protein-linked

receptors)

RN 149831-99-2 CAPLUS

CN 1H-Indole, 3-[2-[[6-O-[5-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)pentyl]-2-O-[(methylthio)thioxomethyl]-3,4-bis-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-35-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-3-[2-[[2,3,4-tris-O-(phenylmethyl)-6-O-[5-[(trifluoroacetyl)amino]pentyl]-β-D-glucopyranosyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-61-1 CAPLUS

CN 1H-Indole, 3-[2-[[6-deoxy-6-[(5-hydroxypentyl)(trifluoroacetyl)amino]-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170219-82-6 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(5-azidopentyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-83-7 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(5-aminopentyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170219-85-9 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(6-azidohexyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 170219-87-1 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-(6-aminohexyl)-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 170220-03-8 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-(5-azidopentyl)-2,3,4-tris-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183051-10-7 CAPLUS
CN 1H-Indole, 3-[2-[[6-O-butyl-2,3,4-tris-O-(phenylmethyl)-β-D-glucopyranosyl]oxy]ethyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 23950 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4 8909 S L3
L5 2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L6 429 S L3 AND PROTEIN
L7 102 S L6 AND INHIBIT?
L8 4 S L7 AND PAIN

=> s l3 and gpcr
8909 L3
4534 GPCR
L9 1 L3 AND GPCR

=> d l9 ed ibib abs hitstr

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 19 Oct 2001
ACCESSION NUMBER: 2001:763315 CAPLUS
DOCUMENT NUMBER: 135:314480
TITLE: Polynucleotides and polypeptides for mammalian T2R taste receptors and their uses
INVENTOR(S): Adler, Jon Elliot
PATENT ASSIGNEE(S): Senomyx, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077676	A1	20011018	WO 2001-US10739	20010404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2403003	A1	20011018	CA 2001-2403003		20010404
EP 1292827	A1	20030319	EP 2001-924619		20010404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003530098	T	20031014	JP 2001-574481		20010404
AU 2001251258	B2	20080605	AU 2001-251258		20010404
NO 2002004809	A	20021209	NO 2002-4809		20021004
MX 2002009843	A	20040906	MX 2002-9843		20021004
US 20040209313	A1	20041021	US 2003-724208		20031201
US 7399601	B2	20080715			
US 20040248149	A1	20041209	US 2003-724209		20031201
US 7393654	B2	20080701			
US 20050069944	A1	20050331	US 2004-986871		20041115
US 7396651	B2	20080708			
US 20070059759	A1	20070315	US 2006-599313		20061115
US 20070061902	A1	20070315	US 2006-599318		20061115
US 20070061903	A1	20070315	US 2006-599319		20061115
US 20070061904	A1	20070315	US 2006-599346		20061115
US 20070061905	A1	20070315	US 2006-599360		20061115
US 20070061906	A1	20070315	US 2006-599392		20061115
US 20070065870	A1	20070322	US 2006-599467		20061115
US 20070065871	A1	20070322	US 2006-599472		20061115
US 20070065873	A1	20070322	US 2006-599487		20061115
AU 2008200999	A1	20080320	AU 2008-200999		20080303
US 20080305542	A1	20081211	US 2008-122052		20080516
US 20090017537	A1	20090115	US 2008-133155		20080604
AU 2008212000	A1	20080925	AU 2008-212000		20080904
PRIORITY APPLN. INFO.:			US 2000-195532P	P	20000407
			US 2000-247014P	P	20001113
			AU 2001-251258	A3	20010404
			WO 2001-US10739	W	20010404
			US 2001-825882	A3	20010405
			AU 2002-318229	A3	20020710
			US 2003-724208	A3	20031201
			US 2003-724209	A1	20031201

AB Newly identified mammalian taste-cell-specific G protein-coupled receptors and cDNAs for said receptors are claimed. Specifically, human and mouse T2R taste G protein-coupled receptors that are believed to be involved in bitter taste sensation are described, along with methods for isolating genes encoding the same and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel mols. or combinations of mols. that elicit a predetd. taste perception in a mammal, and methods for simulating one or more tastes. The identification and isolation of novel taste receptors and taste signaling mols. could allow for new methods of chemical and genetic modulation of taste transduction pathways. Identification of taste modulating compds. could be useful in the pharmaceutical and food industries to improve the taste of consumer products or to block undesirable tastes, for example bitter tastes, in certain products.

IT 6424-12-0, Raffinose undecaacetate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ligand; polynucleotides and polypeptides for mammalian T2R taste receptors and their uses)

RN 6424-12-0 CAPLUS
CN α-D-Glucopyranoside, 1,3,4,6-tetra-O-acetyl-β-D-fructofuranosyl O-2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl-(1→6)-, 2,3,4-triacetate (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 23950 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4 8909 S L3
L5 2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L6 429 S L3 AND PROTEIN
L7 102 S L6 AND INHIBIT?
L8 4 S L7 AND PAIN
L9 1 S L3 AND GPCR

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.40	261.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.74	-5.74

FILE 'REGISTRY' ENTERED AT 13:51:35 ON 28 MAR 2009

```
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAR 2009  HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES:  27 MAR 2009  HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading A:\10.530851.R1A.Meutermans et al..SRNT.CAPLUS..str

L10     STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l10 sss sam
SAMPLE SEARCH INITIATED 13:52:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       59 TO ITERATE

100.0% PROCESSED       59 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          720 TO     1640
PROJECTED ANSWERS:               0 TO        0

L11           0 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 13:52:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1332 TO ITERATE

100.0% PROCESSED     1332 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L12           0 SEA SSS FUL L10

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    186.36     448.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -5.74

FILE 'CAPLUS' ENTERED AT 13:52:54 ON 28 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 Mar 2009  VOL 150 ISS 14
FILE LAST UPDATED: 27 Mar 2009  (20090327/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1             STRUCTURE UPLOADED
L2          50 S L1 SSS SAM
L3       23950 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4        8909 S L3
L5           2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L6         429 S L3 AND PROTEIN
L7         102 S L6 AND INHIBIT?
L8           4 S L7 AND PAIN
L9           1 S L3 AND GPCR

     FILE 'REGISTRY' ENTERED AT 13:51:35 ON 28 MAR 2009
L10            STRUCTURE UPLOADED
L11          0 S L10 SSS SAM
L12          0 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:52:54 ON 28 MAR 2009

=> s l12
L13          0 L12
```

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.50     450.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -5.74

FILE 'REGISTRY' ENTERED AT 13:55:42 ON 28 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAR 2009  HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES:  27 MAR 2009  HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading A:\10.530851.R1B.Meutermans et al..SRNT.CAPLUS..str

L14     STRUCTURE UPLOADED

=> s l14 sss sam
SAMPLE SEARCH INITIATED 13:56:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       83 TO ITERATE

100.0% PROCESSED       83 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1114 TO     2206
PROJECTED ANSWERS:               0 TO        0

L15           0 SEA SSS SAM L14

=> s l14 sss full
FULL SEARCH INITIATED 13:56:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1732 TO ITERATE

100.0% PROCESSED     1732 ITERATIONS                             16 ANSWERS
SEARCH TIME: 00.00.01
```

L16 16 SEA SSS FUL L14

=> d l16 1-2

L16 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 905443-60-9 REGISTRY
ED Entered STN: 30 Aug 2006
CN α-D-Glucopyranoside, phenylmethyl
6-O-[(3-aminophenyl)methyl]-3-O-[(4-carboxyphenyl)methyl]-2-deoxy-2-[(1-oxopropyl)amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H36 N2 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 905443-59-6 REGISTRY
ED Entered STN: 30 Aug 2006
CN β-D-Glucopyranoside, phenylmethyl
6-O-[(3-aminophenyl)methyl]-3-O-[(4-carboxyphenyl)methyl]-2-deoxy-2-[(1-oxopropyl)amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H36 N2 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	190.46	641.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.74

FILE 'CAPLUS' ENTERED AT 13:57:11 ON 28 MAR 2009

FILE COVERS 1907 - 28 Mar 2009 VOL 150 ISS 14
FILE LAST UPDATED: 27 Mar 2009 (20090327/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1             STRUCTURE UPLOADED
L2           50 S L1 SSS SAM
L3        23950 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4         8909 S L3
L5            2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L6          429 S L3 AND PROTEIN
L7          102 S L6 AND INHIBIT?
L8            4 S L7 AND PAIN
L9            1 S L3 AND GPCR

     FILE 'REGISTRY' ENTERED AT 13:51:35 ON 28 MAR 2009
L10            STRUCTURE UPLOADED
L11           0 S L10 SSS SAM
L12           0 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:52:54 ON 28 MAR 2009
L13           0 S L12

     FILE 'REGISTRY' ENTERED AT 13:55:42 ON 28 MAR 2009
L14            STRUCTURE UPLOADED
L15           0 S L14 SSS SAM
L16          16 S L14 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:57:11 ON 28 MAR 2009

=> s l16
L17           2 L16

=> d l16 ed ibib abs hitstr 1-2
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> d l17 ed ibib abs hitstr 1-2

L17  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
ED   Entered STN:  10 Aug 2006
ACCESSION NUMBER:        2006:792162  CAPLUS
DOCUMENT NUMBER:         145:224891
TITLE:                   Classes of compounds that interact with integrins
INVENTOR(S):             Meutermans, Wim; West, Michael Leo; Thanh Le, Giang;
                         Halliday, Judy; Clark, Christopher
PATENT ASSIGNEE(S):      Alchemia Limited, Australia
SOURCE:                  PCT Int. Appl., 44pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2006081616        A1    20060810    WO 2006-AU129          20060202
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU 2006209794	A1	20060810	AU 2006-209794	20060202
CA 2593749	A1	20060810	CA 2006-2593749	20060202
EP 1843760	A1	20071017	EP 2006-704810	20060202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008528639	T	20080731	JP 2007-553414	20060202
US 20080176936	A1	20080724	US 2007-813737	20070711
CN 101111243	A	20080123	CN 2006-80003935	20070802
PRIORITY APPLN. INFO.:			AU 2005-900499 A	20050204
			WO 2006-AU129 W	20060202

OTHER SOURCE(S): MARPAT 145:224891
GI



I

AB A method of inhibiting or modulating the activity of an integrin receptor which comprises contacting an integrin with a compound of formula I, or a pharmaceutically acceptable salt. Compds. of formula I wherein the ring may be of any configuration; Z = sulfur, oxygen, CH2, NH, NRA or hydrogen, Z = hydrogen then R1 is not present, RA is selected from the set defined for R1 to R5, X = oxygen or NRA providing that at least one X of general formula I = NRA, X may also combine independently with one of R1 to R5 to form an azide, R1 to R5 independently = H, -(CO)R6 or alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1-20 atoms which is optionally substituted, and can be branched or linear wherein substituents may optionally be further substituted, wherein R6 = alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituent of 1 to 20 atoms, which is optionally substituted, and can be branched or linear wherein substituents may optionally be further substituted, with the proviso that XR2 or XR3 or XR4 or XR5 is not NH2, and further not more than one of R2 to R5 = H, where the group X is NRA and RA is not hydrogen, the groups RA and the corresponding group R2 to R5 may combine to form a cycle. Compds. of the invention were assayed for inhibition of integrin receptors αvβ3 binding to fibrinogen and αIIbβ3 binding to fibrinogen and vitronectin.

IT 905442-51-5 905442-52-6 905442-86-6
905442-87-7 905442-94-6 905442-95-7
905443-38-1 905443-40-5 905443-51-8
905443-52-9 905443-59-6 905443-60-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino-substituted carbohydrate derivs. as integrin modulators)

RN 905442-51-5 CAPLUS
CN β-D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-(carboxymethyl)-2-[(4-chlorobenzoyl)amino]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905442-52-6 CAPLUS
CN α-D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-(carboxymethyl)-2-[(4-chlorobenzoyl)amino]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905442-86-6 CAPLUS
CN β-D-Glucopyranoside, ethyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-bromophenyl)methyl]-2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905442-87-7 CAPLUS
CN α-D-Glucopyranoside, ethyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-bromophenyl)methyl]-2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 905442-94-6 CAPLUS
CN β-D-Glucopyranoside, ethyl 6-O-[(3-aminophenyl)methyl]-2-(benzoylamino)-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905442-95-7 CAPLUS
CN α-D-Glucopyranoside, ethyl 6-O-[(3-aminophenyl)methyl]-2-(benzoylamino)-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-38-1 CAPLUS
CN β-D-Glucopyranoside, phenylmethyl 6-O-[(3-aminophenyl)methyl]-2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-3-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-40-5 CAPLUS
CN α-D-Glucopyranoside, phenylmethyl
6-O-[(3-aminophenyl)methyl]-2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-3-O-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-51-8 CAPLUS
CN β-D-Glucopyranoside, phenylmethyl
2-(acetylamino)-6-O-[(3-aminophenyl)methyl]-3-O-(carboxymethyl)-2-deoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-52-9 CAPLUS
CN α-D-Glucopyranoside, phenylmethyl
2-(acetylamino)-6-O-[(3-aminophenyl)methyl]-3-O-(carboxymethyl)-2-deoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-59-6 CAPLUS
CN β-D-Glucopyranoside, phenylmethyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-carboxyphenyl)methyl]-2-deoxy-2-[(1-oxopropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905443-60-9 CAPLUS
CN α-D-Glucopyranoside, phenylmethyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-carboxyphenyl)methyl]-2-deoxy-2-[(1-oxopropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ED Entered STN: 23 Apr 2004
ACCESSION NUMBER: 2004:333585 CAPLUS
DOCUMENT NUMBER: 140:350624
TITLE: Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)
INVENTOR(S): Meutermans, Wim; Thanh, Giang Le; Abbenante, Giovani; Tometzki, Gerald; Halliday, Judy; Zeugg, Johannes
PATENT ASSIGNEE(S): Alchemia Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032940	A1	20040422	WO 2003-AU1347	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499677	A1	20040422	CA 2003-2499677	20031010
AU 2003266858	A1	20040504	AU 2003-266858	20031010
AU 2003266858	B2	20060914		
EP 1549325	A1	20050706	EP 2003-747740	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703228	A	20051130	CN 2003-80101113	20031010
JP 2006504718	T	20060209	JP 2004-542106	20031010
US 20060223764	A1	20061005	US 2003-530851	20031010
IN 2005KN00858	A	20060609	IN 2005-KN858	20050511
IN 2007KN03028	A	20071130	IN 2007-KN3028	20070817

PRIORITY APPLN. INFO.:	AU 2002-951995	A	20021011
	WO 2003-AU1347	W	20031010
	IN 2005-KN858	A3	20050511

OTHER SOURCE(S): MARPAT 140:350624
GI



I

AB The invention discloses a method of inhibiting or effecting the activity of a GPCR which comprises contacting a GPCR with a compound I [Z = S, O, NRA (RA = R1-R5, C1-15 acyl, etc.); X = O, NRA; R1-R5 = H, C1-12 alkyl, C4-15 aryl, etc.; with provisos; ring may be of any configuration], or a pharmaceutically acceptable salt thereof. Libraries of compds. of the

invention were tested for activity in assays using melanocortin and somatostatin receptors.

IT 681150-28-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrahydropyran compds. that interact with G protein-coupled receptors)

RN 681150-28-7 CAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:28:49 ON 28 MAR 2009)

FILE 'REGISTRY' ENTERED AT 13:29:01 ON 28 MAR 2009
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 23950 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:32:41 ON 28 MAR 2009
L4 8909 S L3
L5 2 S L4 AND G (W) PROTEIN (W) COUPLED (W) RECEPTOR
L6 429 S L3 AND PROTEIN
L7 102 S L6 AND INHIBIT?
L8 4 S L7 AND PAIN
L9 1 S L3 AND GPCR

FILE 'REGISTRY' ENTERED AT 13:51:35 ON 28 MAR 2009
L10 STRUCTURE UPLOADED
L11 0 S L10 SSS SAM
L12 0 S L10 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:52:54 ON 28 MAR 2009
L13 0 S L12

FILE 'REGISTRY' ENTERED AT 13:55:42 ON 28 MAR 2009
L14 STRUCTURE UPLOADED
L15 0 S L14 SSS SAM
L16 16 S L14 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:57:11 ON 28 MAR 2009

L17 2 S L16